Trials / Conditions / Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

19 registered clinical trials studyying Gastric or Gastroesophageal Junction Adenocarcinoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined W NCT07400315	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Not Yet Recruiting	Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroe NCT07408609	Jiangsu Cancer Institute & Hospital	Phase 2
Recruiting	Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su NCT07115485	Shanghai Henlius Biotech	Phase 2
Not Yet Recruiting	Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Lo NCT07151209	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Recruiting	Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of P NCT06841679	Beijing Biostar Pharmaceuticals Co., Ltd.	Phase 2 / Phase 3
Not Yet Recruiting	Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/ NCT07091227	Peking Union Medical College Hospital	Phase 2
Recruiting	The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment i NCT06587425	Shanghai Zhongshan Hospital	Phase 2
Active Not Recruiting	Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ NCT05941481	Jiangsu Cancer Institute & Hospital	Phase 2
Recruiting	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With NCT05482893	Phanes Therapeutics	Phase 1 / Phase 2
Unknown	Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer NCT05994456	Sun Yat-sen University	Phase 2
Unknown	SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positiv NCT05218148	Aiping Zhou	Phase 2
Completed	Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negativ NCT06440811	Xijing Hospital	—
Completed	Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma NCT04192734	Hallym University Medical Center	—
Unknown	PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Aden NCT04098796	China Medical University, China	Phase 2
Completed	A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469	Xencor, Inc.	Phase 1
Completed	A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398	Xencor, Inc.	Phase 1
Completed	Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advan NCT03777657	BeiGene	Phase 3
Completed	A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488	Xencor, Inc.	Phase 1
Completed	A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adeno NCT02340975	MedImmune LLC	Phase 1 / Phase 2